Listen
Reason for request
Inclusion
-
Clinical Benefit
| Substantial |
The actual benefit of EURARTESIM in the treatment of uncomplicated Plasmodium falciparum malaria is substantial. |
Clinical Added Value
| minor |
Given its efficacy in the treatment of uncomplicated malaria, particularly in the case of multidrug-resistant strains and a lower risk of developing resistance with combinations containing artemisinin derivatives compared with traditional monotherapies, particularly in children and in malaria-endemic areas (particularly in French Guian a and Mayotte), the proprietary medicinal product EURARTESIM, like the proprietary medicinal product RIAMET, provides a minor improvement in actual benefit (IAB IV) in the treatment of uncomplicated Plasmodium falciparum malaria. |
